Literature DB >> 8646236

The ileal neobladder--updated experience with 306 patients.

P Flohr1, R Hefty, T Paiss, R Hautmann.   

Abstract

From April 1986 through May 1995, 306 men with primary urothelial carcinoma underwent radical cystoprostatectomy and orthotopic bladder substitution via the ileal neobladder. Altogether, 7.5% of the patients suffered general early complications, including thrombosis, embolism, wound infection, and pneumonia. Specific early complications directly related to formation of the neobladder and requiring surgery included ileus (4%), abscess drainage (2%), and leakage of the ileal anastomosis (0.5%). The early reoperation rate was 6.5%. Early complications that required temporary percutaneous drainage were lymphocele formation (3%) or ureteral obstruction (6%). In all, 9% of our patients required prolonged catheter drainage for leakage of the ileouretheral anastomosis. Late complications requiring reoperation were ileus (2%), abscess drainage (1%), neobladder fistula to the colon (1.5%), ureteral reimplantation because of obstruction (3.6%), and nephrectomy for hydronephrosis (1%). A transurethral incision of the ileouretheral anastomosis was necessary in 7% of cases. Continence was separately addressed by sending each patient and his home physician a detailed questionnaire: Using our criteria (no diapers, no awakenings) the night and day continence rate increased from 67% at 6 months, to 72% at 1 year to 85% at 2 years, finally reacting 90% after 4 years. In part II of this presentation we address the question as to whether the option of orthotopic bladder replacement has any impact on the patient's and physician's decision toward earlier cystectomy. We compared our ileal neobladder cohort with a group of 137 patients that had been operated on during the same time span by the same group of surgeons. There was no negative selection with regard of the tumor stage of our patients. However, as compared with the conduit group, the neobladder cohort had a significantly improved survival rate. This phenomenon is explainable by the significantly lower number of previous transurethral resections of the bladder (TUR-Bs) performed in the neobladder group. The time span between primary diagnosis and cystectomy was 10 months in the neobladder group as compared with 18 months in the conduit patients. These data reinforce our belief that orthotopic bladder replacement using the ileal neobladder yields an extraordinary functional result that can be accomplished with a high degree of patient satisfaction and minimal complication. The availability of orthotopic bladder replacement does indeed stimulate the physicians and patients decision toward earlier cystectomy.

Entities:  

Mesh:

Year:  1996        PMID: 8646236     DOI: 10.1007/bf01836340

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  9 in total

1.  Ileal bladder substitute: antireflux nipple or afferent tubular segment?

Authors:  U E Studer; T Spiegel; G A Casanova; J Springer; E Gerber; D K Ackermann; F Gurtner; E J Zingg
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

2.  The ileal neobladder.

Authors:  R E Hautmann; G Egghart; D Frohneberg; K Miller
Journal:  J Urol       Date:  1988-01       Impact factor: 7.450

3.  Continence after total bladder replacement: urodynamic analysis of the ileal neobladder.

Authors:  R Bachor; D Frohneberg; K Miller; G Egghart; R Hautmann
Journal:  Br J Urol       Date:  1990-05

4.  [The ileal neobladder].

Authors:  R E Hautmann; G Egghart; D Frohneberg; K Miller
Journal:  Urologe A       Date:  1987-03       Impact factor: 0.639

Review 5.  Options in replacement cystoplasty following radical cystectomy: high hopes or successful reality.

Authors:  F E Martins; C J Bennett; D G Skinner
Journal:  J Urol       Date:  1995-05       Impact factor: 7.450

6.  [Continent urinary diversion in the elderly patient. Results with an ileum neobladder].

Authors:  K Miller; R Bachor; D Frohneberg; G Egghart; R Hautmann
Journal:  Urologe A       Date:  1990-03       Impact factor: 0.639

7.  The ileal neobladder: experience and results of more than 100 consecutive cases.

Authors:  U K Wenderoth; R Bachor; G Egghart; D Frohneberg; K Miller; R E Hautmann
Journal:  J Urol       Date:  1990-03       Impact factor: 7.450

8.  The ileal neobladder: 6 years of experience with more than 200 patients.

Authors:  R E Hautmann; K Miller; U Steiner; U Wenderoth
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

9.  Impact of anatomical radical prostatectomy on urinary continence.

Authors:  M S Steiner; R A Morton; P C Walsh
Journal:  J Urol       Date:  1991-03       Impact factor: 7.450

  9 in total
  6 in total

Review 1.  The use of small intestine in bladder reconstruction.

Authors:  K M Kashif; S A Holmes
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 2.  Bladder replacement in women: a new experience.

Authors:  M Racioppi; A D'Addessi; A Alcini; E Alcini
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1997

3.  Local recurrence in patients after radical cystectomy and orthotopic ileal neobladder: impact on function.

Authors:  Ralph Oberneder; Stephan Staudte; Raphaela Waidelich; Nikolaus Schmeller; Alfons Hofstetter
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

4.  Orthotopic neobladder versus ileal conduit urinary diversion after cystectomy--a quality-of-life based comparison.

Authors:  Joe Philip; Ramaswamy Manikandan; Suresh Venugopal; John Desouza; Pradip M Javlé
Journal:  Ann R Coll Surg Engl       Date:  2009-06-25       Impact factor: 1.891

5.  National survey on orthotopic neobladder.

Authors:  N P Gupta; M S Ansari; Gholam Nabi
Journal:  Int Urol Nephrol       Date:  2007       Impact factor: 2.266

6.  Morbidity and Quality of Life in Bladder Cancer Patients following Cystectomy and Urinary Diversion: A Single-Institution Comparison of Ileal Conduit versus Orthotopic Neobladder.

Authors:  Barbara Erber; Mark Schrader; Kurt Miller; Martin Schostak; Daniel Baumunk; Anja Lingnau; Andres Jan Schrader; Florian Jentzmik
Journal:  ISRN Urol       Date:  2012-02-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.